The ZBTB33 antibody targets the zinc finger and BTB domain-containing protein 33 (ZBTB33), also known as Kaiso, a transcription factor involved in epigenetic regulation and gene silencing. ZBTB33 contains a BTB/POZ domain at its N-terminus, which mediates protein-protein interactions, and C-terminal zinc finger motifs that bind methylated DNA sequences or specific non-methylated motifs (e.g., the Kaiso binding site, CTGCNA). It plays dual roles in gene regulation: as a methyl-dependent repressor, it silences promoters with methylated CpG islands, often associated with tumor suppressor genes in cancers; independently of methylation, it regulates genes involved in development, Wnt/β-catenin signaling, and cell adhesion. Dysregulation of ZBTB33 is linked to tumor progression, immune evasion, and neurological disorders. Antibodies against ZBTB33 are widely used in techniques like Western blotting, ChIP-seq, and immunofluorescence to study its localization, DNA-binding activity, and interactions with epigenetic modifiers (e.g., DNA methyltransferases, histone deacetylases). These tools have advanced research into cancer epigenetics, particularly in understanding how ZBTB33 mediates crosstalk between DNA methylation and transcriptional repression. Its therapeutic potential as a target for cancers with aberrant methylation profiles remains under active investigation.